BioSante Pharmaceuticals to Present At BIO Emerging Company Investor Forum.

LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (AMEX:BPA) announced today that Phillip Donenberg, chief financial officer, will be presenting at the BIO Emerging Company Investor Forum in San Francisco at 9:30 a.m. PDT (12:30 p.m. EDT) on October 15, 2004.

Mr. Donenberg will discuss the company's product pipeline of hormone therapy products, including positive data recently reported on LibiGel(TM) transdermal testosterone gel for the treatment of female sexual dysfunction, as well as its calcium phosphate (CAP) nanotechnology under development for drug delivery and vaccines. A Web cast of the presentation will be available on BioSante's Web site at http://www.biosantepharma.com/investors/events.htm approximately one hour after the conclusion of the presentation, and will be archived for one year.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis. The transdermal gel formulations used in the hormone therapy products are licensed from Antares Pharma, Inc. (Amex:AIS). The estrogen and testosterone markets in the United States alone account for over $2.5 billion in annual sales.

The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at www.biosantepharma.com.